partial chronology of China-Western biotech events


Pfizer's Milestones in China https://www.pfizer.com.cn › pfizer-china › pfizer_s_miles... Ever since entering the China market in the 1980s, Pfizer has been committed to contributing to both the economic development of China and the health of …………………………...................…  Gates Foundation pledged US$ 750 million to set up Gavi in 1999. The Foundation is a key Gavi partner in vaccine market shaping. The Bill & Melinda Gates Foundation | Gavi, the Vaccine Alliance
https://www.gavi.org › funding › donor-profiles › bill-... …………………....................…. May 7, 2014 — The public-private partnership between the Gates Foundation, TB alliance and Fosun Pharma aims to develop and commercialize a new TB drug in ... TB Alliance Announces Partnership with Hongqi Pharma to ... https://www.tballiance.org.za › news › tb-alliance-anno... ………………….................... 1 year ago China building Bio Weapon that can target people based on race. China has been amassing a disturbing amount of genetic data from the rest of the world, and it's been doing it for something nightmarish. … China's Nightmarish New Bio Weapon Targets ... - YouTube https://www.youtube.com/watch?v=biNxl7tiVSY toward the video end the 2016 Chinese biotech weapon plan is discussed ……………………………….................. Under the terms of the agreement, Fosun Pharma has agreed to make an equity investment of USD 50 million (EUR 44 million) for 1,580,777 ordinary shares in BioNTech, subject to execution of share subscription documentation and approval from regulatory authorities in China.Mar 16, 2020 BioNTech and Fosun Pharma form COVID-19 vaccine ... https://investors.biontech.de › news-release-details › biont... ……………………......................... https://www.businesswire.com/news/home/20200722005438/en/ “We’ve been committed to making the impossible possible by working tirelessly to develop and produce in record time a safe and effective vaccine to help bring an end to this global health crisis,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We made the early decision to begin clinical work and large-scale manufacturing at our own risk to ensure that product would be available immediately if our clinical trials prove successful and an Emergency Use Authorization is granted. We are honored to be a part of this effort to provide Americans access to protection from this deadly virus.” “Expanding Operation Warp Speed’s diverse portfolio by adding a vaccine from Pfizer and BioNTech increases the odds that we will have a safe, effective vaccine as soon as the end of this year,” said HHS Secretary Alex Azar…. “BioNTech is the market authorization holder worldwide and will hold all trademarks for the potential product. Both collaborators are committed to developing these novel vaccines with pre-clinical and clinical data at the forefront of all their decision-making. “We are pleased to have signed this important agreement with the U.S. government to supply the initial 100 million doses upon approval as part of our commitment to address the global health threat. This agreement is one of many steps towards providing global access to a safe and efficacious vaccines for COVID-19. We are also in advanced discussions with multiple other government bodies and we hope to announce additional supply agreements soon. Our goal remains to bring a safe and effective COVID-19 vaccine to many people around the world, as quickly as we can,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech…. No serious adverse events were reported. On July 20th, the companies announced early positive update from German Phase 1/2 COVID-19 vaccine study, including first T Cell response data ………………........................... 

-Fosun CEO Fosun Pharma unit, BioNTech to form joint venture to make up ... https://www.scmp.com › Business › Companies May 9, 2021 — A unit of Shanghai Fosun Pharmaceutical has agreed to form a US$200 million joint venture with German partner BioNTech to build a plant in China ……………………………...................... State Department identifies two Chinese bioweapons sites Beijing refuses meeting to discuss germ weapons concerns ………………………….....................…. By Bill Gertz - The Washington Times April 28, 2022 China carried out offensive biological weapons work until 1987 and failed to disclose the full extent of the activities for years as required under an international agreement, according to the State Department’s annual report on arms treaty compliance. Additionally, Chinese officials for the second year in a row have refused a meeting with U.S. counterparts to discuss ongoing concerns about China’s biological ………………………........................… Inovio, advancing COVID-19 shot, scores DOD deal to scale ...
https://www.fiercepharma.com › pharma DOD deal to scale up needleless vaccine devices By Eric Sagonowsky COVID-19drug delivery systemDepartment of DefenseInovio Pharmaceutical INOVIO Pharmaceuticals, Inc. also scored a much larger contract from the U.S. government for delivery devices.  The U.S. Department of Defense (DOD) inked a $71 million supply deal with the Pennsylvania biotech to manufacture devices that use electrical pulses to deliver the company’s vaccines into the skin. The biotech’s vaccine candidate entered human testing in April, and the company plans to report results from that study this month.   The DOD deal will support manufacturing of Inovio's next-gen Cellectra 3PSP and purchase of its older Cellectra 2000.  ......................... AmerisourceBergen Dec 5, 2022 (AmerisourceBergen) The biosimilars market in the United States is poised to experience significant growth in the coming year and beyond, driven—in part—by greater uptake and an acceleration in FDA approvals and product launches.
Slowed by disruptions caused by the COVID-19 pandemic, the biosimilars market has rebounded in 2022 as the FDA has approved six products, including the first biosimilars within retina-ophthalmology. The approved products—which nearly match the total (7) from the two previous years combined—offer the potential to expand patient access to high-quality biologics and generate cost savings across healthcare. In fact, since the first biosimilar approval in 2015, biosimilars have generated more than $13 billion in savings.
And more movement is on the horizon. With at least seven biosimilars referencing AbbVie’s blockbuster Humira (adalimumab) set to launch in the coming year, 2023 could serve as a pivotal time for the industry.
Humira, which is used to treat an array of inflammatory diseases, is the world’s top-selling pharmaceutical product, generating upward of $20 billion in revenue in 2021. To date, the FDA has approved seven biosimilars referencing Humira, with Amgen’s biosimilar set to launch in the first quarter of 2023.
Many pharmaceutical industry stakeholders are closely monitoring decisions made around wholesale acquisition cost (WAC), PBM (pharmacy benefits manager) coverage, support services and patient and provider education, said Beth McMahon, Senior Vice President for Global Emerging Therapies and Channel Strategies at AmerisourceBergen, a global healthcare company. Optum Rx recently announced it plans to place up to three of the biosimilars on its formulary at parity with Humira.
The Centers for Medicare & Medicaid Services (CMS) recently finalized the proposed rule to continue its policy to make all biosimilars eligible for pass-through payment—and not just the first biosimilar biological product for a reference product.
 – just last week Teva Pharmaceutical Industries and Sandoz said they are planning a significant ramp-up in production of biosimilars. https://www.fiercepharma.com/pharma/inovio-scores-71m-department-defense-deal-to-scale-up-vaccine-delivery-devices ………………………..................... Space race 2.0: China is building weapons to attack U.S. ‘ground, sea, or air targets from orbit’ 52 minutes ago By Bill Gertz ……………...................…